Clinical trials: Pharmacogenomics
Breast Neoplasms, Tamoxifen
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast…
- Trial name
- MHSLabCorp1 (NCT00830973)
- Testing
- Poor Metabolism Status Follow Up Therapy Considerations, CYP2D6 Inhibiting Drugs
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Medco Health Solutions, Inc.
Pharmacogenetic Testing, Elderly
Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly
Pharmacist-led pharmacogenomics (PGx) clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by CareKinesis d/b/a Tabula Rasa…
- Conditions
- Pharmacogenetic Testing, Elderly, Opioid Use, Pain
- Trial name
- NCT04971902
- Testing
- Pharmacogenetic Test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Tabula Rasa HealthCare
SCLC
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets'…
- Trial name
- Drug-SNP (NCT07145333)
- Testing
- Topotecan - usual, Topotecan - study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Ulcerative Colitis, Inflammatory Bowel Disease
Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy…
- Trial name
- NCT00038922
- Testing
- rhIL-11
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Genetics of Drug Metabolism
Utility of PharmacoGenomics for Reducing Adverse Drug Effects
UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency…
- Trial name
- UPGRADE (NCT02081872)
- Where
- 41 sites in United States
- Volunteers
- 279,000 people
- Sponsor
- Companion Dx Reference Lab, LLC
Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
- Trial name
- NCT04770922
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cipherome, Inc.
Obesity, Diabetes Mellitus Type 2
Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus
The purpose of this study is to explore the mode of action of topiramate in the treatment of obese and diabetic patients by testing association between genetic variations within candidate genes or chromosomes (thread like…
- Trial name
- NCT00304603
- Testing
- No intervention
- Volunteers
- 1,145 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug-Related Side Effects and Adverse Reactions, Iatrogenic Disorder
Association Between Genetic Variant Scores and DOACs (DARES2)
The study's objective is to evaluate the predictive accuracy of Cipherome's algorithm in predicting and preventing serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).
- Trial name
- NCT04597593
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Colorectal Neoplasms
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
This protocol describes procedures for the collection of blood samples for the intent of determining genetic contribution to the safety and efficacy of CPT/FU/LV.
- Trial name
- NCT00140036
- Testing
- Blood draw
- Where
- 34 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- Pfizer
Breast Cancer
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.
- Trial name
- Drugs-SNPs (NCT06062810)
- Testing
- Raloxifene - Usual, Raloxifene - Study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Prostate Cancer
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will…
- Trial name
- Drugs-SNPs (NCT03348670)
- Testing
- Abiraterone - Usual, Abiraterone - Study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Atrial Fibrillation, Deep Vein Thrombosis
Association Between Genetic Variant Scores and Warfarin Effect
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
- Trial name
- AWARE1 (NCT03894878)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Pharmacogenomic Testing for Medication Management
Reduction of Adverse Drug Events and Readmissions
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
- Trial name
- RADAR-PGX (NCT02738047)
- Where
- United States
- Volunteers
- 280,000 people, healthy volunteers welcome
- Sponsor
- ClinLogic LLC
Depression
Pharmacogenetic-Directed Treatment for Major Depression
Determine if antidepressant treatment guided by pharmacogenetic algorithm and interpretive report improves outcomes when compared with standard treatment without the availability of genetic information.
- Trial name
- NCT01261364
- Testing
- GeneSightRx, Treatment as usual
- Volunteers
- 50 people
- Sponsor
- Assurex Health Inc.
Pharmacogenomics, Medication Therapy Management
A Pharmacist Implemented Pharmacogenomics Service in the Program of All-inclusive Care for the Elderly
The aim of this study is to evaluate and describe the feasibility of implementing a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- PACE (NCT03257605)
- Volunteers
- 296 people
- Sponsor
- Tabula Rasa HealthCare
Psoriasis
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
This is a phase I, open label, single group study that is being performed to assess the safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single dose of spesolimab in adult patients with…
- Trial name
- NCT02978690
- Testing
- Spesolimab
- Where
- 6 sites in France, Japan and 4 more
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of…
- Trial name
- NCT00415038
- Testing
- Rostafuroxin
- Where
- Belgium
- Volunteers
- 438 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Adverse Drug Event, Drug Drug Interaction
Implementation of a Pharmacist-led Pharmacogenomic Clinical Service
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services.
- Conditions
- Adverse Drug Event, Drug Drug Interaction, Pharmacogenomics, Elderly
- Trial name
- NCT04984538
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare